US · Healthcare · Medical Instruments & Supplies
EPS came in at -0.46 against a street estimate of -0.61 — a beat of 24.6%.
Analysts rate Kestra Medical Technologies, Ltd. Common Stock a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $30.00.
CONFIDENT Kestra delivered 60% YoY revenue growth to $31M in Q1 FY27, raised FY27 guidance to $141M (+48% YoY), and expanded gross margin to 56.5%. Company is investing heavily in AI, commercial expansion, and R&D while maintaining path to profitability. Q1 FY27 Analysts pressed hard on beat magnitude and guidance raise (why raise more than beat), quarterly cadence, gross margin upside drivers, and payer coverage gaps. Management emphasized KPI strength across fill/bill/collections and ramp timing of 2026 rep cohorts. On new R&D project, executives withheld detail until next quarter despite pressure. 2026-09-14…
Full summary in the app.
| Fund | Stake |
|---|---|
| Bain Capital Investors LLC | 42.95% |
| T. Rowe Price Associates, Inc. | 10.18% |
| FMR Inc | 9.76% |
| Andera Partners | 4.66% |
| Yu Fan | 3.89% |
| Brown Advisory Holdings Inc | 2.94% |
| BlackRock Inc | 2.88% |
| Eventide Asset Management, LLC | 2.47% |
| Document | Date |
|---|---|
| Quarterly report · Q1 FY2027 KESTRA MEDICAL TECHNOLOGIES, LTD. — 10-Q SUMMARY Quarter Ended July 31, 2026 --- HEADLINE NUMBERS • Revenue: $30,971K (Q1 2026) vs. $19,371K (Q1 20 | 2026-09-14 |
| Results announced · Q2 FY2027 KESTRA MEDICAL TECHNOLOGIES – Q1 FY2027 SUMMARY HEADLINE NUMBERS • Revenue: $31.0 million in Q1 FY2027, up 60% year-over-year (prior year: $19.4 mil | 2026-09-14 |
| Shareholder vote results · Q2 FY2027 KESTRA MEDICAL TECHNOLOGIES, LTD. – 8-K SUMMARY HEADLINE NUMBERS • Annual general meeting held September 9, 2026 • Total shares voted: 55,399,491 (9 | 2026-09-10 |
| Proxy statement · Q2 FY2027 KESTRA MEDICAL TECHNOLOGIES, LTD. - PROXY STATEMENT SUMMARY HEADLINE NUMBERS • Annual Meeting scheduled for Wednesday, September 9, 2026, at 9:00 a. | 2026-07-28 |
| Annual report FY2026 KESTRA MEDICAL TECHNOLOGIES, LTD. – 10-K SUMMARY HEADLINE NUMBERS • Fiscal year ended April 30, 2026 • IPO completed March 7, 2025 on Nasdaq (ticker | 2026-07-14 |
| Results announced · Q1 FY2027 KESTRA MEDICAL TECHNOLOGIES - FY2026 FINANCIAL SUMMARY HEADLINE NUMBERS • FY26 revenue: $95.1 million — 59% increase vs. FY25 ($59.8 million) • Q4 F | 2026-07-14 |
| Quarterly report · Q3 FY2026 KESTRA MEDICAL TECHNOLOGIES, LTD. — 10-Q SUMMARY (Q3 FY2026) --- HEADLINE NUMBERS • Revenue (9 months ended Jan 31, 2026): $66,488K vs. $42,582K pr | 2026-03-17 |
| Results announced · Q4 FY2026 KESTRA MEDICAL TECHNOLOGIES – Q3 FY2026 SUMMARY HEADLINE NUMBERS • Q3 FY26 revenue: $24.6 million (63% increase vs. prior year Q3) • Gross margin: 5 | 2026-03-17 |
Readable in the app.
| Announcement | Date |
|---|---|
| FY27 revenue guidance raised to $141 million, representing 48% growth Kestra Medical Technologies reported strong first quarter fiscal 2027 results with impressive growth. Revenue hit $31 million, up 60% year-over-year, driven by expansion in their wearable ca | 2026-09-14 |
| FY27 revenue guidance of $137 million, 44% increase versus FY26 Kestra Medical Technologies reported strong financial results for fiscal year 2026 (ended April 30, 2026). Revenue grew 59% year-over-year to $95.1 million, with Q4 revenue of $28.6 million | 2026-07-14 |
| FY26 revenue guidance raised to $93 million, 55% growth Kestra Medical Technologies reported strong Q3 fiscal 2026 results with impressive growth. Revenue hit $24.6 million, up 63% year-over-year, driven by 5,462 prescriptions for their ASSURE we | 2026-03-17 |
| FY26 revenue guidance raised to $91 million, representing 52% growth Kestra Medical Technologies, a wearable defibrillator device company, reported strong Q2 fiscal 2026 results with 53% revenue growth to $22.6 million, driven by increased prescriptions (4,69 | 2025-12-11 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kestra Medical Technologies, Ltd. Common Stock — free to start.
Google PlayApp StoreData updated 2026-09-18.